DNA Repair reagents: Novus Biologicals

NB100-309

ATM Antibody (2C1) - Azide and BSA Free

(3 Reviews)

(132 Publications)

100 ul

NB100-309

Western Blot: ATM Antibody (2C1) [NB100-309] - Analysis of ATM in U2OS sarcoma cells using ATM antibody (2C1) [NB100-309]. Theoretical molecular weight 351 kDa. Western blot image submitted by a verifeid customer review.

Immunohistochemistry-Paraffin: ATM Antibody (2C1) [NB100-309] - Human Kidney (formalin-fixed, paraffin-embedded) stained with ATM antibody (2C1) [NB100-309] at 5 ug/ml followed by biotinylated anti-mouse IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.

<b>Genetic Strategies Validation. </b>Western Blot: ATM Antibody (2C1) [NB100-309] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (60 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody (2C1) [NB100-309] diluted at 1:500.

<b>Genetic Strategies Validation. </b>Western Blot: ATM Antibody (2C1) [NB100-309] - Methylated EDSBs may be repaired by an ATM-dependent pathway. Immunoblots of ATM and DNA-PKcs in ATM shRNA-transfected HeLa cells, using ATM antibody (2C1) [NB100-309]. GAPDH is included as a loading control. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-70), licensed under a CC-BY license.

Immunoprecipitation: ATM Antibody (2C1) [NB100-309] - MDA-MB-231 whole cell lysates were immunoprecipitated with 2 ug ATM Antibody (NB100-309), followed by Western blot (primary antibody: NB100-309 at 1:1000, 4C overnight. Western blot image submitted by a verified customer review.

<b>Biological Strategies Validation. </b>Western Blot: ATM Antibody (2C1) [NB100-309] - MCELNs decreased the DNA damage of H9C2 cells after radiation. Western blot images of p-ATM (NB100-306) and ATM (NB100-309) in H9C2 cells after 48 h of culture with indicated treatment. IR (-/+): 0/16 Gy X-ray; MCELNs (-/+): 0/10 ug/mL. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35509278/) licensed under a CC-BY license.

Western Blot: ATM Antibody (2C1) [NB100-309] - Western blot analysis of the extent of knockdown MRE11 & ATM, & the lack of effect of Mirin activation of ATM. The extent of shRNA-mediated knockdown of MRE11 & ATM are shown for (A) clones GFP-7F1 & GFP-6D1 & (B) clones EDS-7F2 & EDS-6J8. The extent of knockdown was determined by analyzing the intensity of the ATM & MRE11 bands relative to the intensity of the loading control GAPDH bands (see Table 1). (C) The effect of Mirin on activation of ATM was determined by analysis of phosphorylation of ATM in response to ionizing radiation. Cultures treated with DMSO alone, 20 μM Mirin, or knockdown of ATM were analyzed by western blot 30 min after exposure to 10 Gy of ionizing radiation. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26209132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ATM Antibody (2C1) [NB100-309] - Rac1 inhibition abolishes IR-induced activation of both ATM & ATR signaling. (A) MCF-7 cells were treated with/without 20-Gy IR in the presence or absence of 100 μM NSC23766 & incubated for 1 hour at 37°C before analysis. To assess the ATM kinase activity, ATM was immunoprecipitated from cell lysate by using anti-ATM antibody (2C1) & assayed for ATM activity by using p53 recombinant protein as substrate. To measure the Chk2 activity, Chk2 was immunoprecipitated from cell lysate by using B-4 anti-Chk2 antibody & assayed for Chk2 activity by using Cdc25C recombinant protein as substrate. As controls, ATM & Chk2 protein levels in the immunoprecipitates (IP-WB) as well as in cell lysates (WB) were assessed with immunoblotting. (B) ATR & Chk1 were immunoprecipitated from cell lysates by using N-19 anti-ATR & G-4 anti-Chk1 antibody, respectively. ATR activity was assayed by using p53 recombinant protein substrate, & Chk1 activity assayed by using Cdc25C recombinant protein substrate. As controls, ATR & Chk1 protein levels in the immunoprecipitates (IP-WB), as well as in cell lysates (WB) were assessed with immunoblotting. (C) MCF-7 cells were exposed to IR at the indicated doses in the presence or absence of NSC23766, incubated for 1 hour, & assessed for Chk1 & Chk2 activities. *Kinase assay does not contain Cdc25C substrate. (D) T47D & ZR-75-1 cells were exposed to 10-Gy IR in the presence or absence of 100 μM NSC23766, incubated for 1 hour, & analyzed for Chk1 & Chk2 activities. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3164), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ATM Antibody (2C1) [NB100-309] - Inhibition of Rac1 by N17Rac1 mutant or Rac1 siRNA diminishes IR-induced G2/M checkpoint activation. (A) MCF-7 cells were infected with Ad.N17Rac1 or Ad.Control for 24 hours & exposed to 15-Gy IR. Left panel: the cells were analyzed for DNA content 24 hours after IR. The result depicts the percentage of cells with 4N-DNA content & is shown as mean ± SD of quadruplicate samples. *P < 0.001 (n = 4), significant difference from the irradiated Ad.Control-infected cells. Right panel: Inset: at 15 minutes after IR, the infected cells were analyzed for Rac1 activities (Rac1-GTP) & protein levels (total Rac1). Bar graph: mitotic cells in the cell samples were analyzed 2 hours after IR. The result depicts the percentage of mitotic cells & is shown as mean ± SD of triplicate samples. **P = 0.002 (n = 3), significant difference from the irradiated Ad.Control-infected cells. (B) Upper panel: MCF-7 cells transfected with Rac1 siRNA (Rac1) or control siRNA (Control) were incubated for the indicated times & analyzed for protein levels of Rac1 & Actin. Lower panel: After 2-day incubation, the siRNA-transfected cells were exposed to IR, incubated for 24 hours, & assessed for DNA content. Results depict the percentage of cells with 4N-DNA content & represent the mean ± SD of three separate experiments in duplicate samples. *P < 0.001 (n = 6), significant difference from the irradiated Control-siRNA transfected cells. (C) After 2-day incubation, siRNA-transfected cells were treated with/without 20-Gy IR, incubated for 1 hour, & analyzed for ATM, ATR, Chk1, & Chk2 activities. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3164), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ATM Antibody (2C1) [NB100-309] - HeLa whole cell extract and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody [2C1] (NB100-309) diluted at 1:500. The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody.

Western Blot: ATM Antibody (2C1) [NB100-309] - Whole cell extract (30 ug) was separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody [2C1] (NB100-309) diluted at 1:1000.

Human Testis (formalin-fixed, paraffin-embedded) stained with ATM antibody at 5 ug/ml followed by biotinylated anti-mouse IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.

Reactivity:

Hu, Mu, Rt, Pm

Species Glossary

Reactivity: Hu, Mu, Rt, Pm

Applications:

, , , , , , , , ,

Applications: , , , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Conjugate:

Unconjugated

Validated by:

Validated by:

compare

(select up to 3 products from this page to compare)

NB100-104

ATM Antibody - BSA Free

(2 Reviews)

(100 Publications)

0.1 ml

NB100-104

<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: ATM Antibody [NB100-104] - GM00637 cells with KU55933 pretreatment (a) were exposed to 50 uM spermidine or CCCP, followed by immunofluorescence analyses of total and p-ATM on Ser-1981. The scale bar is 10 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep24700) licensed under a CC-BY license.

Flow Cytometry: ATM Antibody [NB100-104] - An intracellular stain was performed on HeLa cells with Dylight 550-conjugated ATM Antibody [NB100-104R] (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.

<b>Biological Strategies Validation. </b>Western Blot: ATM Antibody [NB100-104] - Analysis of double strand break repair in MCF-7 monolayer and mammosphere populations. Expression of proteins involved in the NHEJ pathway of DSB repair in response to increasing doses of ionizing radiation. Lysates were prepared from unirradiated cells and from cells harvested one hour after exposure to 1 or 10-Gy 60Co I3-radiation and analyzed by immunoblotting with antibodies against several DSB repair proteins. Phospho-ATM and phospho-DNA-PKcs refer to phosphorylation of these proteins at Ser1981 and Ser2056, respectively. Actin served as a loading control. Image collected and cropped by Citeab from the following publication (Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res (2010)) licensed under a CC-BY license.

Western Blot: ATM Antibody [NB100-104] - Detection of ATM in Raji whole cell lysate using [NB100-104]. Observed molecular weight ~300 kDa. Theoretical molecular weight 351 kDa.

Immunocytochemistry/Immunofluorescence: ATM Antibody [NB100-104] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.05% Triton X-100. Then cells were incubated with [NB100-104] at a 1:100 dilution overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Flow Cytometry: ATM Antibody [NB100-104] - Analysis of PE conjugate of ATM Antibody [NB100-104PE]. An intracellular stain was performed on HeLa cells with ATM antibody [NB100-104PE] (blue) and a matched isotype control [NBP2-24893PE] (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin.

Flow Cytometry: ATM Antibody [NB100-104] - An intracellular stain was performed on HepG2 cells with PE-conjugated ATM antibody [NB100-104PE] (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.

Immunocytochemistry/ Immunofluorescence: ATM Antibody [NB100-104] - ATM is activated by spermidine in GM00637 cells.GM00637 cells with or without KU55933 pretreatment (a,b), & GM05849 cells (c) were exposed to 50 μM spermidine or CCCP, followed by immunofluorescence analyses of total & p-ATM on Ser-1981. The scale bar is 10 μm. Ratios of cells expressing p-ATM Ser-1981 to cells expressing total ATM were presented (d). 20–45 cells/condition from three experiments were collected. Values are mean ± SD, *p < 0.05 vs. control. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep24700), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ATM Antibody [NB100-104] - Depletion of SMARCAL1 induces DNA damage & checkpoint activation in iSML1 iPSCs. (A,B) The iSML1 iPSCs were cultured for 7 & 14 days in the presence of doxycycline (DOX) to induce SMARCAL1 downregulation & then immunostained. The graphs (top) show quantification of the number of gamma -H2AX-positive cells (A) or ATM-pSer1981-positive cells (B). Representative images from triplicate experiments are shown (bottom). (C) Immunoblot detection of the indicated DDR proteins in iSML1 iPSCs after 14 days of continuous treatment with DOX. Lamin B1 was used as the loading control. Data are mean±s.e.m. from three independent experiments. *P≤0.05, **P≤0.01, ***P≤0.001 (two-way ANOVA test). ns, not significant. Scale bars: 10 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31515241), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ATM Antibody [NB100-104] - Analysis of double strand break repair in MCF-7 monolayer & mammosphere populations. (a) Cells were exposed to 4 Gy 60Co gamma -radiation & the relative degree of double-strand breakage (DSB) was determined by the comet assay under neutral conditions immediately after exposure & at the times indicated after exposure. (b) The 'comets' (n of about 100) were categorized according to the NIH LISTSERV (Comet Assay Interest Group web site) in which type 1 comets display the least DNA damage & type 5 the most. The error bars represent the mean ± standard error of the mean in both panels. The comets of the unirradiated cells are labeled Cont. (c) Expression of proteins involved in the NHEJ pathway of DSB repair in response to increasing doses of ionizing radiation. Lysates were prepared from unirradiated cells & from cells harvested one hour after exposure to 1 or 10-Gy 60Co gamma -radiation & analyzed by immunoblotting with antibodies against several DSB repair proteins. Phospho-ATM & phospho-DNA-PKcs refer to phosphorylation of these proteins at Ser1981 & Ser2056, respectively. Actin served as a loading control. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2583), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Ca, Ma

Species Glossary

Reactivity: Hu, Mu, Rt, Ca, Ma

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 405	NB100-104AF405
Alexa Fluor 488	NB100-104AF488
Alexa Fluor 647	NB100-104AF647
Alexa Fluor 700	NB100-104AF700
Biotin	NB100-104B
DyLight 405	NB100-104V
DyLight 488	NB100-104G
DyLight 550	NB100-104R
DyLight 594	NB100-104DL594
DyLight 650	NB100-104C
FITC	NB100-104F
HRP	NB100-104H
PE	NB100-104PE

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB100-104SS

compare

(select up to 3 products from this page to compare)

NB100-116

APE Antibody (13B8E5C2) - BSA Free

(3 Reviews)

(111 Publications)

0.1 mg

NB100-116

Immunocytochemistry/Immunofluorescence: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE Antibody (13B8E5C2) [NB100-116] - HeLa cells stained NB100-116 (Green) detected with DyLight Fluor 488 conjugated anti-rabbit IgG secondary antibody. Nuclei are counterstained with Hoechst 33258 (Blue).

Immunohistochemistry: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE Antibody (13B8E5C2) [NB100-116] - Immunohistochemical staining of APE1. A. Nuclear staining in the luminal epithelium of normal breast ducts and lobules. B. Low, and C. high nuclear APE1 expression in invasive breast cancer. (magnification x400). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0099528) licensed under a CC-BY license.

<b>Biological Strategies Validation. </b>Chromatin Immunoprecipitation (ChIP): APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE Antibody (13B8E5C2) [NB100-116] - Association of p53 and APE1 on p53-binding sites in p21 promoter. Re-ChIP analysis (first IP with alpha-APE1 and the second IP with alpha-p53 antibody) showing simultaneous recruitment of APE1 and p53 in control vs. EPE treated cells; *: p value <0.05 (n=2) calculated based on APE1/p53 enriched DNA from control vs. etoposide treated cells. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0068467) licensed under a CC-BY license.

Simple Western: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE Antibody (13B8E5C2) [NB100-116] - Image shows a specific band for APE1 in 0.1 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody.

Immunocytochemistry/Immunofluorescence: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE Antibody (13B8E5C2) [NB100-116] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-APE (13B8E5C2) at 5 ug/mL overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Western Blot: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE Antibody (13B8E5C2) [NB100-116] - Ovarian Cancer cell lines.

Immunocytochemistry/Immunofluorescence: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE Antibody (13B8E5C2) [NB100-116] - Immunocytochemical detection of APE-ref-1 in breast cancer cell line MDA MB 231.

Immunohistochemistry-Paraffin: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE Antibody (13B8E5C2) [NB100-116] - APE1 antibody was tested in human breast cancer xenograft using DAB with hematoxylin counterstain.

Chromatin Immunoprecipitation: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Association of APE1 & AP4 in p21 proximal promoter region.(A & B) ChIP Real Time PCR analysis showing relative enrichment of (A) APE1 & (B) AP4 in p21 proximal promoter containing AP4-responsive E-Box elements in HCT116p53null cells. (C) Re-ChIP (first IP with alpha -APE1 & the second IP with alpha -AP4 antibody) analysis showing simultaneous recruitment of APE1 & AP4 in this promoter region. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23874636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Effect of APE1 on p21 activation in p53 WT cells.(A) Western analysis for APE1 level in WT APE1 & N delta 42 APE1 overexpressing cells. (B) Real Time RT-PCR analysis showing relative quantitation of p21 transcript level in etoposide-treated WT APE1-overexpressing HCT116WT cells & N delta 42 APE1 overexpressing cells; *: p value <0.05 (n = 2) calculated from control (empty vector transfection) vs. WT APE1 overexpression, WT APE1 overexpression along with etoposide treatment or N delta 42 overexpression. (C) Luciferase activity in cells co-transfected with empty or WT APE1-expression vector & p21 promoter-luciferase construct; *: p value <0.05 (n = 2) calculated from control (empty vector transfection) vs. APE1 overexpression. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23874636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Analysis of single strand break repair in MCF-7 monolayer & mammosphere cell populations. (a) Cells were exposed to 4 Gy 60Co gamma -radiation & the relative degree of single-strand breakage (SSB) was determined by alkaline single-cell gel electrophoresis (comet assay) immediately after exposure & at the times indicated after exposure. (b) The 'comets' (n of about 100) were categorized according to the NIH LISTSERV (Comet Assay Interest Group web site) in which type 1 comets display the least DNA damage & type 5 the most. The error bars represent the mean ± standard error of the mean in both panels. The comets of the unirradiated cells are labeled Cont. (c) Expression of proteins involved in SSB repair in response to ionizing radiation. Lysates were prepared from unirradiated cells & from cells harvested one hour after exposure to 1 or 10-Gy 60Co gamma -radiation & analyzed by immunoblotting with antibodies against several SSB repair proteins. alpha -Actin served as a loading control. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2583), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Intracellular APE1/Ref-1 was targeted to the plasma membrane in response to acetylation. (A & B) Whole cell lysates were immunoprecipitated using an anti-acetyl lysine antibody, followed by immunoblotting with the polyclonal anti-APE1/Ref-1 antibody. The blots were stripped & re-probed with anti-beta -actin & APE1/Ref-1 antibody to ensure equal protein loading. Similar results were obtained from replicate experiments. Column, mean (n = 3); bars, SE. *, p < 0.05, significantly different compared with control or between group by one-way ANOVA followed by Bonferroni’s multiple comparison test. (C,D) Membrane fractions or whole cell lysates were prepared from the TSA-treated cells. Immunoblotting for APE1/Ref-1 was performed using the polyclonal anti-APE1/Ref-1 antibody. Blots were stripped & re-probed with anti-N-cadherin & anti-beta -actin antibodies to control for differences in protein loading. Fold changes in the levels of APE1/Ref-1 in the plasma membrane fraction relative to the control are shown. †, indicates molecular marker (N-cadherin) of left image. Column mean (n = 3); bars, SE.*, p < 0.05 indicates a significantly different result compared with control or between groups by one-way ANOVA followed by Bonferroni’s multiple comparison test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31261750), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Immunocytochemistry/ Immunofluorescence: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - AcAPE1 is exclusively associated w/ chromatin & remains bound to condensed chromosomes. (A & B) Asynchronous normal lung fibroblast IMR90 cells & lung adenocarcinoma A549 cells immunostained w/ anti-APE1 & anti-AcAPE1 Abs, counterstained w/ DAPI, & visualized by confocal microscopy & 3D SIM. (C) Colocalization of AcAPE1 w/ histone H3 or active enhancer-specific histone marker acetylated H3K27 (H3K27Ac). (D) BJ-hTERT cells serum starved for 72 h & then fixed at different time points. Cells immunostained w/ anti-APE1 & anti-AcAPE1 Abs & counterstained w/ anti-TO-PRO-3 iodide Ab. (E) Mitotic A549 cells immunostained w/ anti-APE1 & anti-AcAPE1 & visualized by 3D SIM. (F) BJ-hTERT cells either serum starved for 72 h (G0/G1 phase), treated w/ nocodazole (mitotic cells) or aphidicolin (G1/S phase synchronized cells), or untreated, & whole-cell extracts isolated using 150 mM or 300 mM salt-containing lysis buffer. Western blot analysis for anti-APE1 & anti-AcAPE1 levels performed. Anti-HSC70 used as loading control. (G) A proximal ligation assay performed w/ mouse anti-APE1 & rabbit anti-APE1 (mAPE1 & Rabbit-APE1), mouse anti-mouse APE1 & rabbit anti-AcAPE1 (mAPE1 & rAcAPE1), & rabbit anti-AcAPE1 & mouse anti-histone H3 (mHistone H3 & rAcAPE1) to confirm the chromatin association of AcAPE1. Mouse IgG (mIgG) & rabbit anti-AcAPE1 used as a control. At least 50 cells counted for PLA foci. (H) Colocalization of p300 & AcAPE1 on chromatin (DAPI). (I) HCT116 cells transfected w/ E1A & mutant E1A, & at 48 h after transfection, IF performed. Cells immunostained w/ anti-p300 & anti-APE1 or anti-AcAPE1 & counterstained w/ DAPI. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27994014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - XPF is epistatic to APE in the gemcitabine resistance. The expression of XPF and/or APE was suppressed by siRNAs in HeLa cells & the cellular sensitivity to gemcitabine was examined. XPF- or APE-suppressed HeLa cells (closed square & closed triangle, respectively) showed sensitivity to gemcitabine. Cosuppression of XPF & APE (closed circle with dashed line) resulted in the sensitivity to gemcitabine similar to the sensitivity induced by the suppression of XPF or APE individually. A control siRNA (siControl) was used as a control (open diamond). Three independent experiments were performed & averages of surviving fraction are plotted. The error bars show standard deviations. The differences in the gemcitabine sensitivity between the control cells & the cells treated with siXPF, siAPE, or siXPF+siAPE are statistically significant at 10 nM & 50 nM with p<0.05. The western blots showed a significant suppression of XPF (more than 95%) & ~75% reduction in the expression of APE with the siRNA treatment. The cosuppression experiments with two siRNAs, siXPF & siAPE, resulted in similar levels of suppression of each protein induced by individual siRNA (more than 95% reduction in XPF & ~85% reduction in APE). Tubulin was used as a protein loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30941207), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Immunocytochemistry/ Immunofluorescence: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Plasma membrane associated APE1/Ref-1 is bound to ABCA1 in response to acetylation. Cells transiently expressing wild type APE1/Ref-1-FLAG or mutant APE1/Ref-1(K6/7R)-FLAG were treated with 1 µM TSA for 1 h. (A) Whole cell lysates were immunoprecipitated using the monoclonal anti-ABCA1 antibody, followed by immunoblot with the anti-FLAG antibody. (B) For reverse immunoprecipitation, cell lysates were immunoprecipitated with anti-APE1/Ref-1 antibody followed by immunoblot analysis with the polyclonal anti-ABCA1 antibody. Blots were stripped & re-probed with anti-ABCA1 or FLAG antibodies to ensure equal protein loading & no contamination of cellular proteins. Similar results were observed in replicate experiments. Columns, mean (n = 2-3); bars, SE. *, p < 0.05 indicates a significantly different result from control cells according to unpaired t-tests. (C) The binding between APE1/Ref-1 & ABCA1 in the plasma membrane was visualized using with a Duolink II PLA system with primary polyclonal anti-APE1/Ref-1 & monoclonal anti-ABCA1 antibodies (PLA†). The PLA-specific fluorescence which represents the APE1/Ref-1-ABCA1 signal, & the DAPI nuclear staining are in red & blue, respectively. The experiment was repeated multiple times with similar results; the data shown here are from a representative experiment. Optical slices were examined using a 40× oil immersion objective with a 2× zoom factor. Scale bar, 20 µm (×80). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31261750), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE1 acetylation enhances its stability on chromatin & its interaction with downstream BER proteins. (A) Colocalization of ligase III & AcAPE1 in A549 cells. Cells were immunostained with anti-ligase III & anti-AcAPE1 Abs. (B) WT or K5R mutant APE1-overexpressing HEK293T cells were treated with TSA-nicotinamide (NAM) for 6 h or not treated, & the nuclear extract was immunoprecipitated using anti-FLAG Ab & immunoblotted with anti-XRCC1 & anti-FLAG Abs. (C) A549 cells were fixed with paraformaldehyde before (top) or after treatment with Triton X-100 (0.5%) (middle) or Triton X-100 plus salt (100 mM KCl) (bottom) & immunostained with anti-APE1 or anti-AcAPE1 Abs & counterstained with DAPI. (D) Acetylation of APE1 induces a conformational change in APE1. The distinct intrinsic fluorescence emission spectra of APE1 & AcAPE1 at 280 nm are shown. A.U., absorbance units. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27994014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - APE1 is acetylated after binding to AP sites in the chromatin. (A) BJ-hTERT cells were treated with MX (50 mM) for the indicated times. IF was performed using anti-APE1 & anti-AcAPE1, & counterstaining with DAPI was used. (B) HCT116 cells were treated with various doses of MX for 30 min, IF was performed using anti-APE1 & anti-AcAPE1, & counterstaining with DAPI was used. (C) HCT116 cells were treated with 50 mM MX for 30 min, IF was performed using anti-OGG1, & counterstaining with DAPI was used. (D) BJ-hTERT cells pretreated with 50 mM MX for 30 min or not pretreated were exposed to MMS (2 mM) for 1 h. IF was performed using anti-APE1 & anti-AcAPE1, & counterstaining with DAPI was used. Confocal microscopy was used to visualize the AcAPE1 levels in control cells & cells treated with MMS or MX, or both. (E) ChIP with anti-OGG1 antibody followed by Western blotting (ChIP-on-Western) was performed to examine the association of AcAPE1 & ligase III on chromatin after induction of DNA damage with GO. (F) The association of AcAPE1 with the endogenous p21 promoter in control or MMS- or MX-treated cells was examined by promoter-directed ChIP using anti-AcAPE1. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27994014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Repression of p21 by APE1 in p53-null cells & effect of ectopic p53 in this repression.(A & B) Real Time RT-PCR analysis showing relative quantitation of p21 transcript level in (A) HCT116p53null cells with WT & N delta 42 APE1 overexpression; *: p value (n = 4) calculated from control (empty vector transfection) vs. WT or N delta 42 APE1 overexpression, & (B) control (control siRNA) vs. APE1-depleted HCT116p53null cells; *: p value <0.05 (n = 4) calculated from control vs. APE1-depleted cells. (C) Effect of ectopic p53 expression on p21 transcript level in control vs. APE1-depleted HCT116p53null cells. First, cells were transfected with control siRNA or APE1 siRNA, the next day both the cell types were again transfected with empty vector or p53 expression vector & after 48 hrs the cells were harvested; signal from empty vector transfection in both control & APE1-depleted cells were set as reference samples; *: p value <0.05 (n = 3) calculated based on the effect of ectopic p53 expression over empty vector transfection in control vs. APE1-depleted cells. (D) Effect of APE1 depletion in control (empty vector transfected) vs. ectopic p53-expressing HCT116p53null cells; the same experiment was performed as in C but analyzed differently; signal from control siRNA-transfected cells in both empty vector transfected & ectopic p53 expressing cases were set as reference samples; *: p value <0.05 (n = 3) calculated based on the effect of APE1-depletion in empty vector transfected vs. ectopic p53 expressing cells. (E) Representative Western analysis of p53, APE1, p21 & alpha -Tubulin levels in the same HCT116p53null cells as in B–D. (F & G) Real Time RT-PCR analysis of p21 level in Saos2 cells as in C & D. *: p value <0.05 (n = 2). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23874636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Intracellular APE1/Ref-1 was targeted to the plasma membrane in response to acetylation. (A & B) Whole cell lysates were immunoprecipitated using an anti-acetyl lysine antibody, followed by immunoblotting with the polyclonal anti-APE1/Ref-1 antibody. The blots were stripped & re-probed with anti-beta -actin & APE1/Ref-1 antibody to ensure equal protein loading. Similar results were obtained from replicate experiments. Column, mean (n = 3); bars, SE. *, p < 0.05, significantly different compared with control or between group by one-way ANOVA followed by Bonferroni’s multiple comparison test. (C,D) Membrane fractions or whole cell lysates were prepared from the TSA-treated cells. Immunoblotting for APE1/Ref-1 was performed using the polyclonal anti-APE1/Ref-1 antibody. Blots were stripped & re-probed with anti-N-cadherin & anti-beta -actin antibodies to control for differences in protein loading. Fold changes in the levels of APE1/Ref-1 in the plasma membrane fraction relative to the control are shown. †, indicates molecular marker (N-cadherin) of left image. Column mean (n = 3); bars, SE.*, p < 0.05 indicates a significantly different result compared with control or between groups by one-way ANOVA followed by Bonferroni’s multiple comparison test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31261750), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Chromatin Immunoprecipitation: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Association of p53 & APE1 on p53-binding sites in p21 promoter.(A) p21 promoter structure showing p53 & AP4 binding sites. (B) ChIP Real Time PCR analysis showing relative enrichment (2− delta CT) of APE1-immunoprecipitated DNA over that from control IgG in p21 promoter regions containing p53 binding sites 1 & 2 in HCT116WT cells. (C) Re-ChIP analysis (first IP with alpha -APE1 & the second IP with alpha -p53 antibody) showing simultaneous recruitment of APE1 & p53 in control vs. etoposide treated cells; *: p value <0.05 (n = 2) calculated based on APE1/p53 enriched DNA from control vs. etoposide treated cells. (D) Western analysis of FLAG immunoprecipitate (IP) to detect APE1-associated p53 & FLAG (APE1) from empty vector vs. FLAG-tagged WT APE1 or FLAG-tagged N delta 33 APE1 transfected HCT116WT cells (left panel) & from control vs. etoposide-treated WT APE1-FLAG transfected cells (right panel). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23874636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: APE Antibody (13B8E5C2) - BSA Free [NB100-116] - Gemcitabine-induced recruitment of XPF to chromatin depends on APE. HCT116, APE-suppressed HCT116 (HCT116 shAPE), & XPF-deficient HCT116 (HCT116 g4-10) cells were treated with 1 μM of gemcitabine & chromatin fractions were isolated in the indicated time. The presence of XPF & APE was detected by western blots. The asterisk (∗) shows a cross-reacted protein with the anti-XPF antibody. Histone H2AX was used as a loading control. Gemcitabine-induced recruitment of XPF to chromatin (lanes 1-3) was compromised in HCT116 shAPE cell line (lanes 4-5). The chromatin-bound APE is not changed by the gemcitabine treatment (lanes 4-6, Supplementary Figure 5). A signal of XPF (and APE) was normalized with a signal of H2AX in each chromatin fraction using ImageJ software. Then a ratio of chromatin-bound XPF with gemcitabine to XPF in control was determined & depicted as bar graphs. Three independent experiments were performed & averages of the ratio at indicated time points were plotted. The error bars show standard deviations. Only the difference in the chromatin-bound XPF between chromatin from control experiments & chromatin that was incubated one hour with 1 μM gemcitabine is statistically significant in HCT116 (p<0.05). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30941207), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Reactivity:

Hu, Mu, Rt, Pm

Species Glossary

Reactivity: Hu, Mu, Rt, Pm

Applications:

, , , , , , , , , ,

Applications: , , , , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-116AF350
Alexa Fluor 405	NB100-116AF405
Alexa Fluor 488	NB100-116AF488
Alexa Fluor 532	NB100-116AF532
Alexa Fluor 594	NB100-116AF594
Alexa Fluor 647	NB100-116AF647
Alexa Fluor 700	NB100-116AF700
Alexa Fluor 750	NB100-116AF750
Allophycocyanin	NB100-116APC
Biotin	NB100-116B
CoraFluor 1	NB100-116CL1
DyLight 350	NB100-116UV
DyLight 405	NB100-116V
DyLight 488	NB100-116G
DyLight 550	NB100-116R
DyLight 594	NB100-116DL594
DyLight 650	NB100-116C
DyLight 680	NB100-116FR
DyLight 755	NB100-116IR
FITC	NB100-116F
HRP	NB100-116H
Janelia Fluor 525	NB100-116JF525
Janelia Fluor 549	NB100-116JF549
Janelia Fluor 646	NB100-116JF646
Janelia Fluor 669	NB100-116JF669
PE	NB100-116PE
PerCP	NB100-116PCP
mFluor Violet 450 SE	NB100-116MFV450
mFluor Violet 500 SE	NB100-116MFV500
mFluor Violet 610 SE	NB100-116MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB100-116SS
Azide and BSA Free	NBP2-80578

compare

(select up to 3 products from this page to compare)

NBP2-27103

GAPDH Antibody (13H12) - BSA Free

(3 Reviews)

(38 Publications)

0.1 mg

NBP2-27103

Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of human rectal carcinoma tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.

Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - Characterization of lncR492.(B) Northern blot of lncR494 using increasing amounts of loaded total. Black arrow signifies lncR492-specific signal at approximately 1400 bp. A probe targeting Gapdh mRNA served as the loading control. (D) RT-PCR analysis of lncR492 and Gapdh expression. RNA extract was treated with a 5'-phosphate-dependent exonuclease, resulting in a degradation of f.ex. ribosomal RNA.Citation: Winzi M, Casas Vila N, Paszkowski-Rogacz M, Ding L, Noack S, Theis M, et al. (2018) The long noncoding RNA lncR492 inhibits neural differentiation of murine embryonic stem cells. PLoS ONE 13(1): e0191682. //doi.org/10.1371/journal.pone.0191682

Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - Serum from trauma patients induces intrinsic apoptosis resistance by up-regulating AAT expression in neutrophils. AAT protein expression was analyzed in neutrophils after 18 h of culture by western blot analysis. Relative expression was quantified vs. GAPDH expression. One representative blot of five independent experiments is depicted. **p<0.01 (one-way ANOVA with Newman keuls post-hoc test). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0177450), licensed under a CC-BY license.

Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - WB detection of GAPDH protein (theoretical molecular weight 36 kDa) in lysates of Mouse cell lines (A) NIH 3T3 (B) RAW 264.7 using GAPDH antibody (clone 13H12) at a concentration of 0.25 ug/ml.

Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - analysis of GAPDH in HeLa and HEK 293 cells (25ug/lane) using anti-GAPDH antibody. Image from verified customer review.

Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded tissue section of human esophageal squamous cell carcinoma (SCC) using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.

Simple Western: GAPDH Antibody (13H12) [NBP2-27103] - GAPDH/G3PDH Antibody (13H12) [NBP2-27103] - Simple Western lane view shows a specific band for GAPDH in 0.1 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Western Blot: GAPDH Antibody (13H12) - BSA Free [NBP2-27103] - Effect of AAT on Mcl-1 phosphorylation, the activity of MAP kinases & caspases.Neutrophils from healthy volunteers (2.5 × 106/ml) were cultured in medium supplemented with patient serum (3 mg protein/ml; 1%) & those containing low levels of AAT (AAT-reduce serum; 1%) in the presence of STS (0.2 μM). After 3 h, the expression of pMcl-1 (A, n = 7), pAkt (B, n = 8) & pERK1/2 (C, n = 10) were analyzed by western blot. Expression levels of the phosphorylated proteins were normalized to that of the unphosphorylated forms. GAPDH was used as loading control. One representative blot is displayed. *p<0.05; **p<0.01; n.s. = not significant. D. After 4 h of incubation the activities of caspase-9 & caspase-3/-7 were quantified. Results are presented as means ± SEM of eight independent experiments. No significant differences were found (one-way ANOVA with Newman keuls post-hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28493974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Dr, Pm, Pm, Sh, Po, Bv, Ca, Ma, Gp, Re, Sq

Species Glossary

Reactivity: Hu, Mu, Rt, Dr, Pm, Pm, Sh, Po, Bv, Ca, Ma, Gp, Re, Sq

Applications:

, , ,

Applications: , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-6665A

Alt Catalog# IMG-6665A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-27103AF350
Alexa Fluor 405	NBP2-27103AF405
Alexa Fluor 488	NBP2-27103AF488
Alexa Fluor 532	NBP2-27103AF532
Alexa Fluor 594	NBP2-27103AF594
Alexa Fluor 647	NBP2-27103AF647
Alexa Fluor 700	NBP2-27103AF700
Alexa Fluor 750	NBP2-27103AF750
Allophycocyanin	NBP2-27103APC
Biotin	NBP2-27103B
CoraFluor 1	NBP2-27103CL1
DyLight 350	NBP2-27103UV
DyLight 405	NBP2-27103V
DyLight 488	NBP2-27103G
DyLight 550	NBP2-27103R
DyLight 594	NBP2-27103DL594
DyLight 650	NBP2-27103C
DyLight 680	NBP2-27103FR
DyLight 755	NBP2-27103IR
FITC	NBP2-27103F
HRP	NBP2-27103H
Janelia Fluor 525	NBP2-27103JF525
Janelia Fluor 549	NBP2-27103JF549
Janelia Fluor 646	NBP2-27103JF646
Janelia Fluor 669	NBP2-27103JF669
PE	NBP2-27103PE
PerCP	NBP2-27103PCP
mFluor Violet 450 SE	NBP2-27103MFV450
mFluor Violet 500 SE	NBP2-27103MFV500
mFluor Violet 610 SE	NBP2-27103MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP2-27103SS
Azide and BSA Free	NBP2-80749

compare

(select up to 3 products from this page to compare)

NB100-56704

IKK alpha Antibody (14A231) - BSA Free

(87 Publications)

0.1 mg

NB100-56704

Flow Cytometry: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - An intracellular stain was performed on Hek293 cells with IKK alpha Antibody (14A231) NB100-56704 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Western Blot: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - IKK alpha Antibody (14A231) [NB100-56704] - Total protein from various Human, Mouse and Rat cell lines were separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/mL anti-IKK-alpha in 1% non-fat milk in TBST and detected with an anti-mouse HRP secondary antibody using chemiluminescence.

Immunocytochemistry/Immunofluorescence: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - Antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). An antibody dilution of 1:10 was used. Image objective 40X.

Immunohistochemistry: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - B-I. Immunohistochemistry showing the expression of the transgenic protein in N-IKKa and C-IKKa tumors. Staining with NB100-56704 antibody is shown. (B, C) Representative images showing the expression of transgenic IKKa in tumors and adjacent skin of N-IKKa/TgAC mice (B), and C-IKKa/TgAC animals (C). (D, E) Detail showing the nuclear (D) or cytoplasmic (E) localization of the transgenic IKKa in tumors. (F, G) Similar levels of expression of the transgenic IKKa in different N-IKKa tumors. By contrast variable levels of expression of the transgene are observed between different C-IKKa tumors (H, I). t: tumor; s: non-tumoral skin. Scale bar: (B, C) 100um; (D, E) 80 um; (F-I) 200 um. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/article/8792/text/) licensed under a CC-BY license.

Western Blot: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - IKK alpha Antibody (14A231) [NB100-56704] - Analysis of IKK alpha in Daudi cell lysate using IKK alpha antibody at 1 ug/mL.

Immunocytochemistry/Immunofluorescence: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - A431 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-IKK alpha Antibody (14A231) at 2 ug/mL overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Immunocytochemistry/Immunofluorescence: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-IKK alpha Antibody (14A231) at 2 ug/mL overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Immunohistochemistry-Paraffin: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - Analysis of a FFPE tissue section of human kidney using 1:200 dilution of IKK alpha clone 14A231 antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.

Immunohistochemistry-Paraffin: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - Expression of the transgenic IKK alpha protein in skin of C-IKK alpha and N-IKK alpha mice. D-E. Expression of exogenous IKK alpha protein in back skin of 1-month-old mice. Immunostaining with the NB100-56704 anti-IKK alpha antibody is shown. Note the cytoplasmic expression of the transgene in the C-IKK alpha mice (D). By contrast, it is located in the nuclei of cells in the N-IKK alpha mice (E). In both types of transgenic mice the exogenous IKK alpha is expressed in basal keratinocytes (bk), in the outer root sheath of hair follicles (ORS) and in cells surrounding the sebaceous glands (sb). Scale bar: 60um. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/article/8792/text/) licensed under a CC-BY license.

Simple Western: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - IKK alpha Antibody (14A231) [NB100-56704] - Image shows a specific band for IKK alpha in 0.5 mg/mL of Daudi (left) and U937 (right) lysate. This exeriment was performed under reducing conditions using the 12-230 kDa separation system.

Western Blot: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - NEMO-Ub binding is essential for TNF alpha signaling, but not for IL-1 beta signaling.(a) Schematic illustration of NEMO deletions or point mutations. (b,c) Effects of NEMO C-terminal deletion mutants on TNF alpha & IL-1 beta signaling. NEMO−/Y MEFs were reconstituted with mock, NEMO WT or different C-terminal deletion constructs & stimulated with TNF alpha (b) or IL-1 beta (c). Effects on NF-kappa B signaling were investigated by determining I kappa B alpha phosphorylation & degradation in Western Blots as well as NF-kappa B-DNA binding by EMSA. (d,e) Effects of NEMO D311N on TNF alpha & IL-1 beta signaling. NEMO−/Y MEFs were reconstituted with mock, NEMO WT or NEMO D311N point mutant & stimulated with TNF alpha (d) or IL-1 beta (e). Analysis on NF-kappa B signaling were performed as in (b,c). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26740240), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - Expression of the transgenic IKK alpha protein in skin of C-IKK alpha & N-IKK alpha miceA. Recombinant DNA constructs employed to generate both transgenic mice lines. For C-IKK alpha mice generation, the nuclear localization signal (NLS) was removed from the sequence of the human IKK alpha cDNA employed. In the construct used for generation of the N-IKK alpha mice an extra NLS signal was added. WT IKK alpha ; wild type IKK alpha . B. Western blot of total protein extracts showing IKK alpha expression in back skin of Control & C-and N-IKK alpha mice. Actin was used as a loading control. C. Representative example of the K5 staining in back skin section of Control mice. D-E. Expression of exogenous IKK alpha protein in back skin of 1-month-old mice. Immunostaining with the NB100-56704 anti-IKK alpha antibody is showed; similar results were obtained with the H00001147-M04 IKK alpha antibody (not shown). Note the cytoplasmic expression of the transgene in the C-IKK alpha mice (D). By contrast, it is located in the nuclei of cells in the N-IKK alpha mice (E). In both types of transgenic mice the exogenous IKK alpha is expressed in basal keratinocytes (bk), in the outer root sheath of hair follicles (ORS) & in cells surrounding the sebaceous glands (sb). F. Back skin section of Control mice. The NB100-56704 antibody used does not recognize the endogenous IKK alpha in immunohistochemical assays. G. Endogenous IKK alpha expression in control mice using the IKK alpha (sc-7182) antibody. Scale bar: (C) 70 μm; (D-G) 60 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27121058), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Pm

Species Glossary

Reactivity: Hu, Mu, Rt, Pm

Applications:

, , , , , , ,

Applications: , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-136A

Alt Catalog# IMG-136A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-27409AF350
Alexa Fluor 405	NBP2-27409AF405
Alexa Fluor 488	NBP2-27409AF488
Alexa Fluor 532	NBP2-27409AF532
Alexa Fluor 594	NBP2-27409AF594
Alexa Fluor 647	NBP2-27409AF647
Alexa Fluor 700	NBP2-27409AF700
Alexa Fluor 750	NBP2-27409AF750
Allophycocyanin	NBP2-27409APC
Biotin	NBP2-27409B
DyLight 350	NBP2-27409UV
DyLight 405	NBP2-27409V
DyLight 488	NBP2-27409G
DyLight 550	NBP2-27409R
DyLight 594	NB100-56704DL594
DyLight 650	NBP2-27409C
DyLight 680	NBP2-27409FR
DyLight 755	NBP2-27409IR
FITC	NBP2-27409F
HRP	NBP2-27409H
Janelia Fluor 549	NBP2-27409JF549
Janelia Fluor 646	NBP2-27409JF646
PE	NBP2-27409PE
PerCP	NBP2-27409PCP
mFluor Violet 450 SE	NBP2-27409MFV450
mFluor Violet 500 SE	NBP2-27409MFV500
mFluor Violet 610 SE	NBP2-27409MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Azide and BSA Free	NBP2-27409
BSA Free	NB100-56704SS

compare

(select up to 3 products from this page to compare)

NB600-502

GAPDH Antibody (6C5cc) - BSA Free

(3 Reviews)

(87 Publications)

0.2 mg

NB600-502

Western Blot: GAPDH Antibody (6C5) [NB600-502] - Western blot of FGF23 in the kidney. GAPDH antibody (6C5) served as an internal control. Each value represents the mean +/- SEM. Citation: Sugiura H, Matsushita A, Futaya M, Teraoka A, Akiyama K-i, Usui N, et al. (2018) Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model. PLoS ONE 13(3): e0191706. //doi.org/10.1371/journal.pone.0191706

Simple Western: GAPDH Antibody (6C5) [NB600-502] - Simple Western lane view shows a specific band for GAPDH in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Note: band observed higher than predicted 36 kDa molecular weight.

Simple Western: GAPDH Antibody (6C5) [NB600-502] - Anaylsis in rat brain and spinal cord. This image includes the GAPDH at the predicted kDa as well as a glucocorticoid receptor antibody (peak 102). Verified customer review.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - Western blot analysis for whole cell & nuclear signal transduction proteins. (A) Phosphorylated FAK (Y397) was significantly decreased at 24 h & significantly increased at 48 h as compared to sham. (B) Nuclear localization of corresponding signal transduction molecules, p38, & p65, were decreased at 24 h & increased at 48 h as compared to sham. *p 0.05.Immortalized Brca1F/C61G MEFs were infected with retroviruses expressing the indicated shRNAs and/or Cre recombinase, followed by selection with puromycin for 72 h. The frequency of end-to-end chromosome-type fusions was analysed as in (A).MEFs of the indicated genotypes were infected with retroviruses expressing TRF2 and/or CtIP shRNAs, followed by selection with puromycin for 72 h. Cell extracts were prepared 48 h later & analysed by Western blotting as indicated. GAPDH was used as a loading control. *non-specific band. Cells treated as in (C) & (E) were arrested in mitosis with colcemid, & mitotic chromosomes isolated 48 h later were fixed & stained with a Cy3-conjugated (CCCTAA)3-PNA probe (D, F). The frequency of end-to-end chromosome-type fusions is represented as a percentage of fusions observed after TRF2 depletion. Error bars represent SD of two independent experiments. P-values were calculated using an unpaired two-tailed t-test. *P ≤ 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25582120), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Po, Am, Ca, ChHa, Fe, Fi, Rb, Bv(-), Gt(-)

Species Glossary

Reactivity: Hu, Mu, Rt, Po, Am, Ca, ChHa, Fe, Fi, Rb, Bv(-), Gt(-)

Applications:

, , , , ,

Applications: , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB600-502AF350-0.2ml
Alexa Fluor 405	NB600-502AF405-0.2ml
Alexa Fluor 488	NB600-502AF488-0.2ml
Alexa Fluor 532	NB600-502AF532-0.2ml
Alexa Fluor 594	NB600-502AF594-0.2ml
Alexa Fluor 647	NB600-502AF647-0.2ml
Alexa Fluor 700	NB600-502AF700-0.2ml
Alexa Fluor 750	NB600-502AF750-0.2ml
Biotin	NB600-502B-0.2ml
CoraFluor 1	NB600-502CL1
DyLight 350	NB600-502UV-0.2ml
DyLight 405	NB600-502V-0.2ml
DyLight 488	NB600-502G-0.2ml
DyLight 550	NB600-502R-0.2ml
DyLight 594	NB600-502DL594-0.2ml
DyLight 650	NB600-502C-0.2ml
DyLight 680	NB600-502FR-0.2ml
DyLight 755	NB600-502IR-0.2ml
FITC	NB600-502F-0.2ml
HRP	NB600-502H-0.2ml
Janelia Fluor 525	NB600-502JF525
Janelia Fluor 549	NB600-502JF549-0.2ml
Janelia Fluor 646	NB600-502JF646-0.2ml
Janelia Fluor 669	NB600-502JF669
mFluor Violet 450 SE	NB600-502MFV450
mFluor Violet 500 SE	NB600-502MFV500
mFluor Violet 610 SE	NB600-502MFV610

compare

(select up to 3 products from this page to compare)

NB100-101

APE Antibody - BSA Free

(3 Reviews)

(77 Publications)

0.1 ml

NB100-101

Immunohistochemistry: APE Antibody [NB100-101] - Immunohistochemical staining of APE-ref-1 in prostate cancer.

Western Blot: APE Antibody [NB100-101] - RKO cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by immunoblotting (left). Control RKO (RKOSc siRNA) and RKO cells in which TDP1 levels were depleted (RKOTDP1 siRNA) were examined for their survival following exposure to the indicated doses of MMS, as described earlier in the text (right). Increasing the load of unrepaired methylated purines by exploiting the limited availability of TDP1 alone or in combination with canonical BER factors such as APE1 provides a new synthetic lethal setting to improve the clinical outcome of temozolomide-based cancer therapy. Image collected and cropped by CiteAb from the following publication (academic.oup.com/nar/article/42/5/3089/1051107), licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: APE Antibody [NB100-101] - IF on HeLa cells. Image from verified customer review.

Western Blot: APE Antibody [NB100-101] - SH-SY5Y (nuclear extract) tested at 1:1000 dilution. Image provided by verified customer review.

Flow Cytometry: APE Antibody [NB100-101] - Spectral properties of Alexa Fluor(R) 488: an excitation maximum of 490 nm and an emission maximum of 525 nm. Use the Novus Spectra Viewer to identify the optimal laser(s) and filters for Alexa Fluor(R) 488 and to determine its compatibility with other fluorophores when designing a multicolor experiment. //www.novusbio.com/spectraviewer

Western Blot: APE Antibody [NB100-101] - Analysis of APE in human melanoma cell lysate using anti-APE antibody. Image from verified customer review.

Immunocytochemistry/Immunofluorescence: APE Antibody [NB100-101] - Detection of APE1 (Green) in HepG2 cells using NB100-101. Nuclei (Blue) are counterstained with Hoechst 33258.

Western Blot: APE Antibody - BSA Free [NB100-101] - Defective p53 activity leads to failure of the BER coordination system. (A) High-throughput microscopy analysis of TIG-1 cells transfected with plasmids expressing wild-type or mutant p53. Boxplots showing the distribution of APE1 staining intensity (in arbitrary units) in p53 low versus p53 overexpressing cells. Each p53 mutant is reported on top of the relevant plot. The dashed line highlights the median APE1 intensity in p53 low cells (N > 5000). NS: not statistically significant at P 8000). (D) Representative high-throughput immuno-fluorescence pictures showing TIG-1 cells stained for APE1 (right panel) & p53 (middle panel) after transfection with a p53 expressing plasmid. Cells that downregulating APE1 in response to p53 overexpression are marked by a contour line. Image collected & cropped by CiteAb from the following publication (//academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkw015), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: APE Antibody - BSA Free [NB100-101] - Excessive AP-endonuclease activity in cells with p53 impairment leads to accumulation of genomic instability. (A) Representative western blotting analysis on WI38 (SV40) cells shows rescue of gamma H2AX staining upon co-depletion of XRCC1 & APE1. (B) Neutral Comet assay on WI38 (SV40) fibroblasts shows accumulation of DSBs upon XRCC1-depletion & rescue after co-depletion of XRCC1 & APE1. Results are expressed as mean ± SD of three independent experiments. (C) Representative western blotting analysis on WI38 (SV40) cells shows rescue of gamma H2AX staining after depletion of XRCC1 in presence of APE1 inhibitor III (APE1i III, 5 μM for 24 h), or AR03 (2.5 μM for 24 h). Actin was used as loading control in all western blotting experiments. Image collected & cropped by CiteAb from the following publication (//academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkw015), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Pm, Rb

Species Glossary

Reactivity: Hu, Mu, Rt, Pm, Rb

Applications:

, , , , , , , ,

Applications: , , , , , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-101AF350
Alexa Fluor 405	NB100-101AF405
Alexa Fluor 488	NB100-101AF488
Alexa Fluor 532	NB100-101AF532
Alexa Fluor 594	NB100-101AF594
Alexa Fluor 647	NB100-101AF647
Alexa Fluor 700	NB100-101AF700
Alexa Fluor 750	NB100-101AF750
Allophycocyanin	NB100-101APC
Biotin	NB100-101B
CoraFluor 1	NB100-101CL1
DyLight 350	NB100-101UV
DyLight 405	NB100-101V
DyLight 488	NB100-101G
DyLight 550	NB100-101R
DyLight 594	NB100-101DL594
DyLight 650	NB100-101C
DyLight 680	NB100-101FR
DyLight 755	NB100-101IR
FITC	NB100-101F
HRP	NB100-101H
Janelia Fluor 525	NB100-101JF525
Janelia Fluor 549	NB100-101JF549
Janelia Fluor 646	NB100-101JF646
Janelia Fluor 669	NB100-101JF669
PE	NB100-101PE
PerCP	NB100-101PCP
mFluor Violet 450 SE	NB100-101MFV450
mFluor Violet 500 SE	NB100-101MFV500
mFluor Violet 610 SE	NB100-101MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB100-101SS

compare

(select up to 3 products from this page to compare)

NB100-147

Rad50 Antibody (13B3) - Azide and BSA Free

(1 Review)

(79 Publications)

0.1 ml

NB100-147

Immunohistochemistry-Paraffin: Rad50 Antibody (13B3) [NB100-147] - CAL 27 xenograft. Rad50 antibody [13B3] diluted at 1:200. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Immunohistochemistry-Paraffin: Rad50 Antibody (13B3) [NB100-147] - PC-3 xenograft. Rad50 antibody [13B3] diluted at 1:200. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

<b>Genetic Strategies Validation. </b>Western Blot: Rad50 Antibody (13B3) [NB100-147] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Rad50 antibody [13B3].

Western Blot: Rad50 Antibody (13B3) [NB100-147] - Various whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Rad50 antibody [13B3] (NB100-147) diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody.

Rad50 antibody [13B3] detects Rad50 protein at nucleus by immunofluorescent analysis.Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Rad50 protein stained by Rad50 antibody [13B3] (NB100-147) diluted at 1:200.Red: phalloidin, a cytoskeleton marker, diluted at 1:200.Scale bar = 10 ?m.

HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Rad50 antibody [13B3] (NB100-147) diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody.

Reactivity:

Hu, Mu, Rt, Pm

Species Glossary

Reactivity: Hu, Mu, Rt, Pm

Applications:

, , , , ,

Applications: , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Conjugate:

Unconjugated

Validated by:

Validated by:

compare

(select up to 3 products from this page to compare)

NB100-148

Rad51 Antibody (14B4) - Azide and BSA Free

(5 Reviews)

(77 Publications)

100 ul

NB100-148

$Western Blot: Rad51 Antibody (14B4) [NB100-148] - eIF3f facilitates hMSH4 stabilization. Western blotting analysis of the levels of HDAC3, hRad51, and VBP1 expression in 293T, 293T/eIF3f, and 293T/eIF3f-hMSH4 cells. 293T/eIF3f-hMSH4 cells treated with 1 or 10 Gy IR were fractionated at 6 hrs post-treatment and the levels of hMSH4 and eIF3f in the nuclear and cytoplasmic fractions were determined by immunoblotting. Alpha-tubulin was used as a marker for the cytoplasmic fraction. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-12-51) licensed under a CC-BY license.$

Immunohistochemistry-Paraffin: Rad51 Antibody (14B4) [NB100-148] - BT483 xenograft. RAD51 antibody 14B4 dilution at 1:200. Antigen Retrieval: Trilogy(TM) (EDTA based, pH 8.0) buffer, 15 min.

Western Blot: Rad51 Antibody (14B4) [NB100-148] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Rad51 antibody [14B4] diluted at 1:500. The HRP-conjugated anti-mouset IgG antibody (NBP2-19382) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

Immunocytochemistry/Immunofluorescence: Rad51 Antibody (14B4) [NB100-148] - Staining of RAD51 nuclear foci in U2OS cells using RAD51 14B4 antibody. Cells were pre-extracted with CSK buffer before fixation with 4% PFA. RAD51 14B4 was used at 1:1000 dultion. DAPI was used to counterstain the nucleus. Scale bar, 10 mciro-meter.

Immunoprecipitation: Rad51 Antibody (14B4) [NB100-148] - HeLa whole cell extract prepared with lysis 180 buffer (40 mM Tris-HCl pH8.0, 180 mM NaCl, 1 mMEDTA, 0.5% NP-40). Rabbit anti-RAD51 antibody was used for subsequent WB detection of immunoprecipated RAD51.

<b>Genetic Strategies Validation. </b>Western Blot: Rad51 Antibody (14B4) [NB100-148] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Rad51 antibody [14B4].

Western Blot: Rad51 Antibody (14B4) [NB100-148] - YFP-PALB2 & YFP-PALB2 146AAAA binds RAD51 equally.Lysates from HEK293T cells expressing the indicated constructs were subjected to GFP-Trap pulldown & immunoblotting against YFP or RAD51. YFP alone was used as a negative control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31017574), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Rad51 Antibody (14B4) [NB100-148] - Bractoppin Selectively Interrupts BRCA1-Dependent Steps in DNA Repair by Homologous Recombination(A) Confocal images depicting at high magnification the recruitment of the RPA32 protein into nuclear foci after the indicated treatments. Experiments were carried out as described as in Figure 5A. Staining in the upper row is for RPA32 (green), middle row, for mCherry-BRCA1 tBRCT (red); lower row, merged red & green staining, with DNA staining (DAPI) in blue. Scale bar represents 10 μm.(B) Recruitment of RAD51 protein into nuclear foci, measured & depicted as described in (A). Scale bar represents 10 μm.(C) Percentage of cells positive for radiation-induced nuclear RPA32 foci (mean ± SD; n = 5,300, 0 Gy; 3,200, 16 Gy; 3,600, BRCA1 tBRCT; 3,400, Bractoppin; 3,500, CCBT2047) enumerated by high-content imaging (see the STAR Methods). Statistical significance was performed using an unpaired two-tailed t test. ***p ≤ 0.001. Similar results were observed in three independent repeats.(D) Percentage of cells containing nuclear RAD51 foci enumerated & depicted as described in (B). ***p ≤ 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29606576), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Rad51 Antibody (14B4) [NB100-148] - MiCas9’s beneficial effects are Brex27 & RAD51 dependent.a Indel rates by spCas9, miCas9, & miCas9-mutant at the on-target site for sg-AAVS1 & the off-target site 1 for sg-EMX1. b Indel rates estimated by T7E1 assay by spCas9 & miCas9 with or without the use of RAD51 inhibitor, B02. c Co-IP results by using anti-flag (left) or anti-RAD51 (right) antibodies followed western blot for RAD51 or Cas9. d ChIP assay results with anti-RAD51 antibody at the proximal region of the sg-AAVS1 target locus. Sp: spCas9, Mi: miCas9, Mi-mut: miCas9-mutant. #Reads: Average amplicon reads per sample. Three independent experiments were performed for each condition. Data are presented as mean ± standard error of means (SEM). Unpaired t-test (two tailed) was used to compare data using GraphPad Prism 8 software (GraphPad Software, Inc., San Diego, CA). Source data are available in the Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33247137), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Rad51 antibody [14B4] (NB100-148) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident femto Western HRP Substrate.

Reactivity:

Hu, Mu, Rt, Ch

Species Glossary

Reactivity: Hu, Mu, Rt, Ch

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Conjugate:

Unconjugated

Validated by:

Validated by:

compare

(select up to 3 products from this page to compare)

NB300-320

GAPDH Antibody

(2 Reviews)

(69 Publications)

0.1 mg

NB300-320

Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-320] - Staining of paraffin embedded Human Pancreas. Antibody at 2.5 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.

Western Blot: GAPDH Antibody [NB300-320] - stai Mutants Have Reduced Levels of alpha-Tubulin, Acetylated alpha-Tubulin, and Kinesin Heavy Chain Protein. Representative western blots of total protein extracted from stai mutant third instar larvae. Heterozygous stai/+ mutant larvae exhibit mild reductions in the levels of alpha-tubulin and acetylated alpha-tubulin compared with wild type larvae. Homozygous stai mutant larvae have dramatic reductions in the levels of alpha-tubulin, acetylated alpha-tubulin and the heavy chain subunit of the microtubule motor protein kinesin compared to wildtype. Df(2L) BSC239 represents a second chromosomal deficiency that excludes the stai gene. GAPDH is used as a loading control. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0068324), licensed under a CC-BY license.

Western Blot: GAPDH Antibody [NB300-320] - Staining of HEK293 (A) and HeLa (B) cell lysate (35 ug protein in RIPA buffer). Antibody at 0.001 ug/mL. Detected by chemiluminescence. Approx 36 kDa band observed in lysates of cell line HEK293 and approx. 35 kDa in HeLa cell lysates.(calculated MW of 36.1 kDa according to Human NP_002037.2).

Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-320] - Immunofluorescence analysis of paraformaldehyde fixed A549 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic and vesicle staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL). Strong expression of the protein seen in the cytoplasm and vesicles of A549 cells.

Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-320] - Upregulation of GAPDH and Tom20 in C6 gliomas. A small glioma labeled with antibodies against GAPDH. The brightness and contrast have been increased. Image collected and cropped by CiteAb from the following publication (//www.biomedcentral.com/1756-0500/8/207), licensed under a CC-BY license.

Upregulation of GAPDH & Tom20 in C6 gliomas. a A section of rat brain stained with hematoxilin & eosin to show a glioma produced by implantation of C6 cells in the right caudate nucleus. In this case, cells also grew in the region of the syringe needle track through the cortex. (b–d). A small glioma labeled by bisbenzamide (b) & with antibodies against Tom20 (c) & GAPDH (d). The brightness & contrast have been increased. e Illustration of a strip perpendicular to the rim of a glioma (labeled with bisbenzamide) & along which intensity profiles were measured. f, g Tom20 & GAPDH fluorescence along such a strip (barely visible without enhancement). The graphs show the raw intensity values given by ImageJ. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26032618), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody [NB300-320] - PAR2 causes contraction of smooth muscle cells from human prostate. (A & B) Decrease in diameter of collagen hydrogels after PAR2 activation with SLIGKV (80 µM). (C) Representative western blot & (D) densitometry showing time dependent increase in level of phosphorylated MLC20 in PSMC after PAR2 is activated. Data represent mean ± SEM of at least three independent experiments. Diameter of collagen hydrogels were measured in ImageJ (version 1.50i) & significance analyzed in Prism (version 7.04) with one‐way ANOVA followed by Tukey's multiple comparison test. *P < 0.05, **P < 0.01 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31198907), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: GAPDH Antibody [NB300-320] - Upregulation of GAPDH & Tom20 in C6 gliomas. a A section of rat brain stained with hematoxilin & eosin to show a glioma produced by implantation of C6 cells in the right caudate nucleus. In this case, cells also grew in the region of the syringe needle track through the cortex. (b–d). A small glioma labeled by bisbenzamide (b) & with antibodies against Tom20 (c) & GAPDH (d). The brightness & contrast have been increased. e Illustration of a strip perpendicular to the rim of a glioma (labeled with bisbenzamide) & along which intensity profiles were measured. f, g Tom20 & GAPDH fluorescence along such a strip (barely visible without enhancement). The graphs show the raw intensity values given by ImageJ. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26032618), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody [NB300-320] - CDC20B was the protein effector regulated by hsa-miR-633. (a) CDC20B level was up-regulated after ox-LDL treatment revealed by Western blotting. (b) CDC20B level was decreased after the treatment of hsa-miR-633 mimics revealed by Western blotting. (c) CDC20B level was increased after the treatment of hsa-miR-633 inhibitor revealed by Western blotting. (d) The luciferase reporter plasmids were constructed as illustrated. (e) Relative luciferase activities after co-transfection CDC20B WT & hsa-miR-633/Control, or CDC20B Mut & hsa-miR-633/Control were measured. (f) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-CDC20B were measured using Western blotting. (g) Colony formation assay was conducted to examine the proliferation abilityafter the treatment of si-CDC20B. (h) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-CDC20B. (i) Quantification results of (g). (j) Quantification results of (h). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Simple Western: GAPDH Antibody [NB300-320] - MiR-34a affects stroke outcomes via interacting with cytochrome c. (A) WES system image showing CYC, VDAC & GAPDH expression from hemispheres of WT & miR-34a−/− mice at 6 h post-stroke. (B) Relative CYC expression normalized to GAPDH from the data generated by the WES system. CYC level is significantly decreased in ischemic hemispheres of WT mice but no significant changes in miR-34a−/− mice between contralateral hemispheres (Control) & ischemic hemispheres (Ischemia). N = 5 per group, **p < 0.01, One-way ANOVA followed by post hoc Tuckey’s test was used for data analysis. Data are expressed as mean ± S.D. (C) Relative VDAC expression normalized to GAPDH from the data generated by the WES system. VDAC was not significantly altered in WT mice nor miR-34a−/− mice. (D) Multiplexed WES system image showing CYC & GAPDH expression from purified pCECs of WT & miR-34a−/− mice (n = 10 per group, pooled cell samples) at 6 h post-stroke. (E) Relative CYC expression by normalization to GAPDH. A 2.8 fold decrease of CYC level was observed in WT mice but no changes were observed in miR-34a−/− mice between contralateral hemispheres & ischemic hemispheres. (F) A CYC reporter was coexpressed with a miR-34a plasmid, a miR-34a mimic, a miR-34c mimic, or a plasmid control in cultured cerebral vascular endothelial cells for 24 hours. Relative firefly luciferase activity was evaluated & normalized to renilla luciferase activity. Relative firefly luciferase activity was reduced by miR-34a plasmid & miR-34a mimic. The experiment was repeated 3 times & triplicates were used for each analysis. Data represents the mean ± S.D. *p < 0.05. One-way ANOVA followed by post-hoc Tuckey’s test was used for analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32094435), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody [NB300-320] - Hsa-miR-633 inhibitor could reverse the si-circ_0008896 phenotypes. (a) CCK8 assay was conducted to measure cell viability after up-regulation of hsa-miR-633. (b) The expression levels of two proliferation markers, Ki67 & PCNA after up-regulation of hsa-miR-633 were measured using Western blotting. (c) CCK8 assay was conducted to measure cell viability after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (d) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor were measured using Western blotting. (e) Colony formation assay was conducted to examine proliferation ability number of colonies after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (f) Quantification results of (e). (g) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (h) Quantification results of (g). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody [NB300-320] - Down-regulation of hsa_circ_0008896 inhibited proliferation, migration & invasion in vitro. (a) The expression level of hsa_circ_0008896 after si-circ_0008896 transfection was detected using quantitative PCR. (b) CCK8 assay was conducted to measure cell viability after down-regulation of hsa_circ_0008896. (c) The expression levels of two proliferation markers, Ki67 & PCNA after down-regulation of hsa_circ_0008896 were detected using Western blotting. (d) Colony formation assay was conducted to examine proliferation ability after down-regulation of hsa_circ_0008896. (e) The quantification results of (d). (f) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after down-regulation of hsa_circ_0008896. (g) The quantification results of (f). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Ca, Dr, I, Po

Species Glossary

Reactivity: Hu, Mu, Rt, Ca, Dr, I, Po

Applications:

, , , , ,

Applications: , , , , ,

Host:

Goat Polyclonal

Host: Goat Polyclonal

Alt Catalog#

IMG-3073

Alt Catalog# IMG-3073

Conjugate:

Unconjugated

compare

(select up to 3 products from this page to compare)

NB300-327

GAPDH Antibody

(3 Reviews)

(57 Publications)

0.1 ml

NB300-327

Western Blot: GAPDH Antibody [NB300-327] - Theoretical molecular weight: 36 kDa. Detection of GAPDH in mouse liver.

Western Blot: GAPDH Antibody [NB300-327] - Western blot analysis of extracts from Jurkat and HeLa cells using NB300-327 at 1:1000. Theoretical molecular weight: 36 kDa.

$Western Blot: GAPDH Antibody [NB300-327] - Analysis of different cell cytosolic or nuclear enriched fractions, GAPDH antibody, dilution 1:20,000 (Red): [1] protein standard, [2] NIH-3T3 cytosolic, [3] NIH-3T3 nuclear, [4] HeLa cytosolic, and [5] HeLa nuclear fractions. Strong band at 37kDa corresponds to GAPDH protein, mainly detected in the cytosolic fractions. The same blot was simultaneously probed with mouse mAb to the nuclear RNA binding protein SF3B4, dilution 1:1,000 (Green). In contrast to GAPDH, SF3B4 is exclusively expressed in the nuclear fraction.$

Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-327] - The GAPDH antibody was tested in Hela cells at a 1:500 dilution against Dylight 488 (Green). Alpha-tubulin and nuclei were counterstained with Dylight 550 (Red) and DAPI (Blue), respectively.

Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-327] - Confocal immunofluorescence analysis of HeLa cells using GAPDH (NB300-327) antibody (green). Nuclei was counterstained with DAPI (blue).

Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-327] - IF Confocal analysis of C2C12 cells using GAPDH antibody (NB300-327, 1:20). An Alexa Fluor 488-conjugated Goat to rabbit IgG was used as secondary antibody (green). Actin filaments were labeled with Alexa Fluor 568 phalloidin (red). DAPI was used to stain the cell nuclei (blue).

Simple Western: GAPDH Antibody [NB300-327] - Simple Western lane view shows a specific band for GAPDH in 0.2 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Note: band observed higer than predicted 36 kDa molecular weight.

$Western Blot: GAPDH Antibody [NB300-327] - Effects of subchronic administration (7 and 14 days) of therapeutic relevant concentration of Brex (Brex: 300 nM) and interaction between Brex and 5-HT1A receptor (5-HT1AR) antagonist WAY (10 uM) on protein expression of 5-HT1A receptor in the plasma membrane fraction of cortical primary cultured astrocytes. In left side histograms, ordinate: mean +/- SD (n = 6) of the relative protein level of 5-HT1AR per GAPDH. * p < 0.05, ** p < 0.01: relative to control (Brex-free) by one-way analysis of variance (ANOVA) with Tukey’s post-hoc test, and @ p < 0.05: relative to Brex for 14 days by Student’s T-test. Right side panels indicate their pseudo-gel images using capillary immunoblotting. Antibodies used: 5-HT1A (NBP2-21590) and GAPDH (NB300-327). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35743014/) licensed under a CC-BY license.$

Representative immunoblot of KDR and FGFR CAM protein expression levels examined by Western blotting. GNS, graphene nanosheet; NG, graphite nanoparticle; ND, diamond nanoparticle; C60, fullerene C60; MWNT, multi-wall nanotube; KDR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Western Blot: GAPDH Antibody [NB300-327] - Increased PIP expression in the lungs of PF‐PH compared to PF ratsA, BRelative expression of PIP mRNA (A) & protein (B) normalized to GAPDH.CRepresentative images & PIP quantification.Data information: Values are expressed as mean ± SEM. The number of samples per group for each experiment is included within each bar graph (t‐test; *P < 0.05, **P < 0.01). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31468711), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: GAPDH Antibody [NB300-327] - Effects of subchronic administration (7 & 14 days) of therapeutic relevant concentration of Brex (Brex: 300 nM) & interaction between Brex & 5-HT1A receptor (5-HT1AR) antagonist WAY100635 (WAY: 10 μM) on protein expression of 5-HT1A (panel A) & 5-HT7 (panel B) receptor in the plasma membrane fraction of cortical primary cultured astrocytes. In left side histograms, ordinate: mean ± SD (n = 6) of the relative protein level of 5-HT1AR & 5-HT7R per GAPDH. * p < 0.05, ** p < 0.01: relative to control (Brex-free) by one-way analysis of variance (ANOVA) with Tukey’s post-hoc test, & @ p < 0.05: relative to Brex for 14 days by Student’s T-test. Right side panels indicate their pseudo-gel images using capillary immunoblotting. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35743014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Western Blot: GAPDH Antibody [NB300-327] - Online lung microarray analysis revealed PIP as one of the Slug transcriptional targets mediating vascular cell proliferation in PF‐PHAHeatmap of the 20 genes upregulated in GSE24988 microarray & known to be Slug transcriptional target.BVenn diagram showing the overlap between Slug targets implicated in cell proliferation & known to be extracellular.CHeatmap of the seven transcriptional targets of Slug known to promote proliferation & to be extracellular.D, ERelative expression of prolactin‐induced protein (PIP) mRNA (D) & protein (E) expression normalized to GAPDH in PF & PF‐PH patients.FRepresentative images of PIP immunohistochemistry showing its extracellular localization & quantification.G–JProliferation assay on healthy fibroblast (G), pulmonary arterial EC (H), & healthy pulmonary arterial SMC (I & J) in the presence or absence of PIP.Data information: Values are expressed as mean ± SEM. The number of samples per group for each experiment is included within each bar graph. Statistical test: panels (D–F): t‐test; panels (G–J): ANOVA (*P < 0.05, **P < 0.01 ***P < 0.001). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31468711), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody [NB300-327] - Growth of lactobacilli on IECs & their influence towards C. albicans cytotoxicity, adhesion, hyphal length & translocation. (A) LDH release of IECs colonized (Pre-Inc.) or simultaneously colonized (w/o Pre-Inc.) with L. rhamnosus (L.r.) at different MOI (5, 50 or 250) & infected or not with C. albicans (C.a.) (MOI 1) & measured at 24 h post-infection. (B) Growth of L. paracasei (L.p.), L. rhamnosus, L. salivarius (L.s.), L. fermentum (L.f.), & L. brevis (L.b.) on IECs. (C) Percentage of C. albicans adhered to IECs colonized with different Lactobacillus species (MOI 50) at 1 h post-infection. (D) C. albicans hyphal induction on IECs or on plastic colonized with L. rhamnosus or L. brevis (MOI 50) at 4 h post-infection. Results were normalized to C. albicans single infection. (E) Translocation of C. albicans (MOI 1) across IECs colonized with L. rhamnosus or L. brevis (MOI 50) at 24 h post-infection. (F) Assessment of epithelial barrier integrity measured as the loss of transepithelial electrical resistance (TEER) in response to L. rhamnosus or L. brevis (MOI 50) colonization & C. albicans infection in the presence or absence of Lactobacillus colonization at 24 h post-infection. Data are TEER loss in percentage of uninfected host cells (before pre-incubation). (G) E-Cadherin protein expression analyzed by western blot compared to GAPDH in IECs that were left uninfected or colonized with L. rhamnosus (MOI 50) & infected with C. albicans for 6, 12 & 24 h. Data are mean±s.e.m. *P<0.05, **P<0.01, ***P<0.005 (t-test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31413153), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Panel (D) indicates the expression of connexin43 (Cx43) and pannexin1 (PANX1) in the plasma membrane fraction of the PPN between wild type (grey columns) and S286L-TG (black columns). Ordinates indicate the mean � SD (n = 6) of the relative expression of connexin43 and pannexin1 per GAPDH. Right-side panels indicate the pseudo-gel images of connexin43, pannexin1 and GAPDH, obtained using capillary immunoblotting. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/40564986/), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Reactivity:

Hu, Mu, Rt, Po, Ba, Bv, Ch, Eq, Fu, In, Ye

Species Glossary

Reactivity: Hu, Mu, Rt, Po, Ba, Bv, Ch, Eq, Fu, In, Ye

Applications:

, , ,

Applications: , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

compare

(select up to 3 products from this page to compare)

NBP1-49678

PINK1 Antibody - BSA Free

(1 Review)

(3 Publications)

0.1 ml

NBP1-49678

Immunohistochemistry-Paraffin: PINK1 Antibody [NBP1-49678] - Stain in paraffin embedded mouse brain.

Immunocytochemistry/Immunofluorescence: PINK1 Antibody [NBP1-49678] - PINK1 antibody was tested at 1:50 in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Image objective 40x.

Reactivity:

Hu, Mu

Species Glossary

Reactivity: Hu, Mu

Applications:

, , ,

Applications: , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP1-49678AF350
Alexa Fluor 405	NBP1-49678AF405
Alexa Fluor 488	NBP1-49678AF488
Alexa Fluor 532	NBP1-49678AF532
Alexa Fluor 594	NBP1-49678AF594
Alexa Fluor 647	NBP1-49678AF647
Alexa Fluor 700	NBP1-49678AF700
Alexa Fluor 750	NBP1-49678AF750
Allophycocyanin	NBP1-49678APC
Biotin	NBP1-49678B
CoraFluor 1	NBP1-49678CL1
DyLight 350	NBP1-49678UV
DyLight 405	NBP1-49678V
DyLight 488	NBP1-49678G
DyLight 550	NBP1-49678R
DyLight 594	NBP1-49678DL594
DyLight 650	NBP1-49678C
DyLight 680	NBP1-49678FR
DyLight 755	NBP1-49678IR
FITC	NBP1-49678F
HRP	NBP1-49678H
Janelia Fluor 525	NBP1-49678JF525
Janelia Fluor 549	NBP1-49678JF549
Janelia Fluor 646	NBP1-49678JF646
Janelia Fluor 669	NBP1-49678JF669
PE	NBP1-49678PE
PerCP	NBP1-49678PCP
mFluor Violet 450 SE	NBP1-49678MFV450
mFluor Violet 500 SE	NBP1-49678MFV500
mFluor Violet 610 SE	NBP1-49678MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP1-49678SS

compare

(select up to 3 products from this page to compare)

At	=	A. thaliana	SyHa	=	Golden Syrian Hamster
All	=	All Species	Ha	=	Hamster
An	=	Animal	Hu	=	Human
ArHa	=	Armenian Hamster	I	=	Insect
Av	=	Avian	Ll	=	Llama
Bb	=	Baboon	Ma	=	Mammal
Ba	=	Bacteria	Mk	=	Monkey
Bv	=	Bovine	Mu	=	Mouse
Ca	=	Canine	Multi	=	Multi-species
Ce	=	C. Elegans	NA	=	Non-species specific
Ch	=	Chicken	Or	=	Orangutan
ChHa	=	Chinese Hamster	Pl	=	Plant
Cm	=	Cynomolgus Monkey	Pm	=	Primate
Do	=	Donkey	Po	=	Porcine
Dr	=	Drosophilia	Rb	=	Rabbit
Ec	=	E. Coli	Rt	=	Rat
Eq	=	Equine	RM	=	Rhesus Macaque
Fe	=	Feline	Sh	=	Sheep
Ft	=	Ferret	Vb	=	Vertebrate
Fi	=	Fish	Vi	=	Virus
Fu	=	Fungi	Xp	=	Xenopus
Ge	=	Gerbil	Ye	=	Yeast
GP	=	Guinea Pig	Ze	=	Zebrafish
Gt	=	Goat

Category

Protein/Target

Applications

Reactivity

Citation

Antibody Validation

Reviews

Host

Available Conjugates

Format

Marker

Modification

Clonality

Clone

Gene Symbol

Images Type

Isotype

Kit Type

Lysate Type

Preservative

Protein Or Peptide

Research Areas

Has Sample Size

Promotional Item

Species Glossary

ATM Antibody (2C1) - Azide and BSA Free

ATM Antibody - BSA Free

APE Antibody (13B8E5C2) - BSA Free

GAPDH Antibody (13H12) - BSA Free

IKK alpha Antibody (14A231) - BSA Free

GAPDH Antibody (6C5cc) - BSA Free

APE Antibody - BSA Free

Rad50 Antibody (13B3) - Azide and BSA Free

Rad51 Antibody (14B4) - Azide and BSA Free

GAPDH Antibody

GAPDH Antibody

PINK1 Antibody - BSA Free